Qian CN, Zhang W, Xu RH. Defeating cancer: the 150 most important questions in cancer research and clinical oncology. Chin J Cancer. 2016;35:104.
Article
PubMed
PubMed Central
Google Scholar
Wee JT, Poh SS. The most important questions in cancer research and clinical oncology. Question 1 could the vertical transmission of human papilloma virus (HPV) infection account for the cause, characteristics, and epidemiology of HPV-positive oropharyngeal carcinoma, non-smoking East Asian female lung adenocarcinoma, and/or East Asian triple-negative breast carcinoma? Chin J Cancer. 2017;36:13.
Article
PubMed
PubMed Central
Google Scholar
Venniyoor A. The most important questions in cancer research and clinical oncology—question 2–5. Obesity-related cancers: more questions than answers. Chin J Cancer. 2017;36:18.
Article
PubMed
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 6–14. Chin J Cancer. 2017;36:33.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 15–24. Chin J Cancer. 2017;36:39.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 25–30. Chin J Cancer. 2017;36:42.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 31–39. Chin J Cancer. 2017;36:48.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 40–49. Chin J Cancer. 2017;36:55.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 50–56. Chin J Cancer. 2017;36:69.
Article
PubMed Central
Google Scholar
Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 57–66. Chin J Cancer. 2017;36:79.
Article
PubMed Central
Google Scholar
Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, Haick H. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol. 2009;4:669–73.
Article
CAS
PubMed
Google Scholar
Haick H, Broza YY, Mochalski P, Ruzsanyi V, Amann A. Assessment, origin, and implementation of breath volatile cancer markers. Chem Soc Rev. 2014;43:1423–49.
Article
CAS
PubMed
Google Scholar
Hakim M, Broza YY, Barash O, Peled N, Phillips M, Amann A, Haick H. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev. 2012;112:5949–66.
Article
CAS
PubMed
Google Scholar
Broza YY, Kremer R, Tisch U, Gevorkyan A, Shiban A, Best LA, Haick H. A nanomaterial-based breath test for short-term follow-up after lung tumor resection. Nanomedicine. 2013;9:15–21.
Article
CAS
PubMed
Google Scholar
Nakhleh MK, Amal H, Jeries R, Broza YY, Aboud M, Gharra A, et al. Diagnosis and classification of 17 diseases from 1404 subjects via pattern analysis of exhaled molecules. ACS Nano. 2017;11:112–25.
Article
CAS
PubMed
Google Scholar
Broza YY, Mochalski P, Ruzsanyi V, Amann A, Haick H. Hybrid volatolomics and disease detection. Angew Chem Int Ed. 2015;54:11036–48.
Article
CAS
Google Scholar
Peled N, Barash O, Tisch U, Ionescu R, Broza YY, Ilouze M, Mattei J, Bunn PA, Hirsch FR Jr., Haick H. Volatile fingerprints of cancer specific genetic mutations. Nanomedicine (NY, US). 2013;9:758–66.
Article
CAS
Google Scholar
Davies MP, Barash O, Jeries R, Peled N, Ilouze M, Hyde R, Marcus MW, Field JK, Haick H. Unique volatolomic signatures of TP53 and KRAS in lung cells. Br J Cancer. 2014;111:1213–21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Barash O, Zhang W, Halpern JM, Hua QL, Pan YY, Kayal H, Khoury K, Liu H, Davies MP, Haick H. Differentiation between genetic mutations of breast cancer by breath volatolomics. Oncotarget. 2015;6:44864–76.
Article
PubMed
PubMed Central
Google Scholar
Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R’s of radiobiology revisited. Stem cells. 2010;28(4):639–48.
Article
CAS
PubMed
PubMed Central
Google Scholar
Held KD, Kawamura H, Kaminuma T, Paz AE, Yoshida Y, Liu Q, et al. Effects of charged particles on human tumor cells. Front Oncol. 2016;6:23.
Article
PubMed
PubMed Central
Google Scholar
Particle therapy co-operative group. Facilities in Operation. Particle therapy facilities in operation (last update: Semptember 2017). Available at: http://www.ptcog.ch/index.php/facilities-in-operation. Accessed 31 Oct 2017.
Baek SJ, Ishii H, Tamari K, Hayashi K, Nishida N, Konno M, et al. Cancer stem cells: the potential of carbon ion beam radiation and new radiosensitizers (Review). Oncol Rep. 2015;34(5):2233–7.
Article
CAS
PubMed
Google Scholar
Naganawa K, Koto M, Takagi R, Hasegawa A, Ikawa H, Shimozato K, et al. Long-term outcomes after carbon-ion radiotherapy for oral mucosal malignant melanoma. J Radiat Res. 2017;58(4):517–22.
PubMed
Google Scholar
Karube M, Yamamoto N, Tsuji H, Kanematsu N, Nakajima M, Yamashita H, et al. Carbon-ion reirradiation for recurrences after initial treatment of stage I non-small cell lung cancer with carbon-ion radiotherapy. Radiother Oncol. 2017;125(1):31–5.
Article
CAS
PubMed
Google Scholar
Kasuya G, Kato H, Yasuda S, Tsuji H, Yamada S, Haruyama Y, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials. Cancer. 2017;123(20):3955–65.
Article
CAS
PubMed
Google Scholar
Isozaki Y, Yamada S, Kawashiro S, Yasuda S, Okada N, Ebner D, et al. Carbon-ion radiotherapy for isolated para-aortic lymph node recurrence from colorectal cancer. J Surg Oncol. 2017. doi:10.1002/jso.24757.
PubMed
Google Scholar
Shirai K, Saitoh JI, Musha A, Abe T, Kobayashi D, Takahashi T, et al. Prospective observational study of carbon-ion radiotherapy for non-squamous cell carcinoma of the head and neck. Cancer Sci. 2017;108(10):2039–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nomiya T, Tsuji H, Hirasawa N, Kato H, Kamada T, Mizoe J, et al. Carbon ion radiation therapy for primary renal cell carcinoma: initial clinical experience. Int J Radiat Oncol Biol Phys. 2008;72(3):828–33.
Article
PubMed
Google Scholar
Heavy ion cancer therapy. In 2020, heavy ion cancer therapy will begin with a world-leading technology. Yamagata University Hospital. Available at: http://www1.id.yamagata-u.ac.jp/MIDINFO/en/hit/. Accessed 31 Oct 2017.
Durante M, Orecchia R, Loeffler JS. Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol. 2017;14(8):483–95.
Article
PubMed
Google Scholar
McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294(5546):1537–40.
Article
CAS
PubMed
Google Scholar
Cai Y, Crowther J, Pastor T, Abbasi Asbagh L, Baietti MF, De Troyer M, Vazquez I, Talebi A, Renzi F, Dehairs J, et al. Loss of chromosome 8p governs tumor progression and drug response by altering lipid metabolism. Cancer Cell. 2016;29:751–66.
Article
CAS
PubMed
Google Scholar
Liu Y, Chen C, Xu Z, Scuoppo C, Rillahan CD, Gao J, Spitzer B, Bosbach B, Kastenhuber ER, Baslan T, et al. Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature. 2016;531:471–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gao C, Su Y, Koeman J, Haak E, Dykema K, Essenberg C, Hudson E, Petillo D, Khoo SK, Vande Woude GF. Chromosome instability drives phenotypic switching to metastasis. Proc Natl Acad Sci USA. 2016;113:14793–8.
Article
CAS
PubMed
PubMed Central
Google Scholar